Trial Profile
An Open-label, Randomized, Two-way Crossover, Single Dose, Pivotal Bioequivalence Study of a Fixed-dose Combination of Dolutegravir and Rilpivirine in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir/rilpivirine (Primary) ; Dolutegravir; Rilpivirine
- Indications HIV infections
- Focus Pharmacokinetics; Registrational
- Sponsors ViiV Healthcare
- 09 Jul 2018 Results published in the Antimicrobial Agents and Chemotherapy
- 23 Mar 2018 The European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure. The application was supported by SWORD-1 and SWORD-2, and a pivotal bioequivalence study.
- 25 Oct 2016 Status changed from recruiting to completed.